Thermo Fisher Scientific (Waltham, Massachusetts, USA) has announced a $40 million dollar upgrade of its single‑use technology manufacturing facility in Millersburg, Pennsylvania, USA. The expansion comes as part of a long-term, $650 million investment plan unveiled in 2021 to improve bioprocessing production capacity for critical materials used in developing new and existing biologics and vaccines.
The investment will create a new 47,000-square-foot warehouse at the site, with an additional 100 new hires as Thermo Fisher cites its belief that the site will employ more than 1000 workers once it is fully renovated by 2023.
Single-use technologies are essential in the development of a growing number of biological drugs and vaccines, and has created unprecedented demand for these products. The Millersburg site expansion will add significant capacity to continue providing the biopharma industry with the technology and materials needed to assist in developing new vaccines, cancer treatments, and breakthrough therapies for other conditions.
For more information, please visit: https://corporate.thermofisher.com
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ions used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.
Using Chromatography to Explore Fluorescent Bioactive Compounds in the Coelomic Fluid of Earthworms
February 6th 2025A study aiming to identify fluorescent bioactive compounds in the coelomic fluid of earthworms, as well as to investigate their structural and functional characteristics for possible use in biomedical applications, utilized a variety of chromatographic techniques.
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.